Decoupling immunomodulatory properties from lipid binding in the α-pore-forming toxin Sticholysin II

Area of Science:

• Immunology
• Biochemistry
• Marine Biology

Background:

• Sticholysin II (StII) from Stichodactyla helianthus enhances cytotoxic T lymphocyte (CTL) responses.
• StII's immunomodulatory capacity involves pore formation and Toll-like receptor 4 (TLR4) activation in dendritic cells.
• The role of lipid binding in StII's immunomodulation is not fully understood.

Purpose of the Study:

• To investigate if StII's lipid binding is essential for its immunomodulatory effects.
• To characterize a StII mutant (StII3A) lacking lipid binding and pore-forming abilities.
• To evaluate StII3A's potential as a vaccine adjuvant.

Main Methods:

• Site-directed mutagenesis to create StII3A, replacing key aromatic residues (Trp110, Tyr111, Trp114) with alanine.
• Analysis of StII3A's secondary structure and folding.
• Assessment of StII3A's lipid binding and membrane permeabilization capabilities.
• In vivo studies in C57BL/6 mice to evaluate dendritic cell maturation, CD8+ T cell response, and antitumor protection.

Main Results:

• StII3A maintained its secondary structure and overall folding compared to wild-type StII.
• StII3A demonstrated a complete loss of lipid binding and membrane permeabilization.
• Despite lacking lipid binding, StII3A effectively upregulated dendritic cell maturation markers.
• StII3A enhanced antigen-specific effector CD8+ T cell responses and provided antitumor protection in a preventive model.
• These findings suggest a lipid-binding-independent mechanism for StII's immunomodulatory effects.

Conclusions:

• The immunomodulatory capacity of Sticholysin II is not solely dependent on its pore-forming or lipid-binding abilities.
• A modified StII (StII3A) retains significant immunomodulatory functions through a novel mechanism.
• StII3A represents a promising candidate for developing more reliable and potent vaccine adjuvants.